在癌症治疗中ATM抑制剂的开发
Elizabeth A Ampolini1, Judit Jimenez-Sainz1, David T Long2
1Department of Biochemistry and Molecular Biology, Hollings Cancer Center, Medical University of South Carolina, Charleston, SC, 29425, USA.
Targeted oncology
|March 2, 2025
概括
突变性阿塔克西亚-泰朗吉克塔西亚 (ATM) 蛋白激酶抑制剂是有希望的针对DNA损伤的癌症疗法. 研究审查了个性化医学的发展,临床使用,局限性和未来潜力.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 遗传学 遗传学 是一个
背景情况:
- 突变性阿塔克西亚-泰朗吉克塔西亚 (ATM) 蛋白激酶对于DNA双链断裂修复和基因组稳定性至关重要.
- ATM突变在癌症中很常见,造成了可以用于治疗的脆弱性.
- 针对ATM的小分子抑制剂已经成为癌症药物开发的重要领域.
研究的目的:
- 审查ATM抑制剂在癌症治疗中的开发和临床应用.
- 讨论当前ATM抑制剂的局限性和最近的进展.
- 探索ATM抑制剂在个性化医学中的作用,并确定更广泛临床采用的挑战.
主要方法:
- 对ATM抑制剂的临床前和临床研究的文献综述.
- 分析涉及ATM抑制的作用机制和治疗策略.
- 讨论正在进行的临床试验和未来的研究方向.
主要成果:
- ATM 抑制剂在临床前模型中显示出多功能性,并且在临床环境中越来越多地使用.
- 进步导致了针对ATM的临床试验数量和多样性越来越大.
- 了解ATM的作用是开发有效的个性化癌症治疗的关键.
结论:
- ATM 抑制剂对于各种癌症,特别是那些有 ATM 缺陷的癌症,是一种有价值的治疗策略.
- 克服当前的局限性和应对临床应用中的挑战对于最大限度地发挥ATM抑制剂的益处至关重要.
- 对ATM的功能和抑制剂开发的进一步研究对个性化瘤学具有重大前景.
更多相关视频
09:19Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo
Published on: February 6, 2015
8.3K
10:33Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors
Published on: October 26, 2015
11.3K
相关概念视频
02:57Targeted Cancer Therapies
7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.4K
02:34Inhibition of Cdk Activity
4.6K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.6K
02:56Treatment Resistant Cancers
3.2K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.2K
02:50Combination Therapies and Personalized Medicine
4.8K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.8K
01:15Drugs that Stabilize Microtubules
2.0K
Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.0K
01:10Drugs that Destabilize Microtubules
1.9K
Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...
1.9K